1
Clinical Trials associated with Fecal Microbiota(Portland VA Medical Center)A Phase II Single Arm Study of Fecal Microbiota Transplant (FMT) in Men With Metastatic Castration Resistant Prostate Cancer Whose Cancer Has Not Responded to Enzalutamide + Pembrolizumab
All patients will be required to have a biopsy of a metastatic tumor deposit at study entry. Pembrolizumab will be administered at a dose of 200 mg as a 30 minute IV infusion every 3 weeks. Enzalutamide will be continued at dose of 160 mg orally every day. Patients who have neither rapid disease progression or disease response will undergo a fecal microbiota transplant, have a second biopsy (if medically feasible), and be re-treated with pembrolizumab.
100 Clinical Results associated with Fecal Microbiota(Portland VA Medical Center)
100 Translational Medicine associated with Fecal Microbiota(Portland VA Medical Center)
100 Patents (Medical) associated with Fecal Microbiota(Portland VA Medical Center)
100 Deals associated with Fecal Microbiota(Portland VA Medical Center)